Pure Global

A Phase 2a Study of LAM-001 for the Treatment of PH - Trial NCT05798923

Access comprehensive clinical trial information for NCT05798923 through Pure Global AI's free database. This Phase 2 trial is sponsored by AI Therapeutics, Inc. and is currently Recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05798923
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05798923
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase 2a Study of LAM-001 for the Treatment of PH
A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension

Study Focus

Pulmonary Hypertension

LAM-001

Interventional

drug

Sponsor & Location

AI Therapeutics, Inc.

Boston, United States of America

Timeline & Enrollment

Phase 2

Apr 03, 2023

Feb 28, 2025

15 participants

Primary Outcome

Change from baseline VO2 max

Summary

This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy
 for the treatment pulmonary hypertension.

ICD-10 Classifications

Primary pulmonary hypertension
Other secondary pulmonary hypertension
Pulmonary heart disease and diseases of pulmonary circulation
Pulmonary heart disease, unspecified
Pulmonary valve disorders

Data Source

ClinicalTrials.gov

NCT05798923

Non-Device Trial